IL133277A0 - Ligands, including antibodies, showing reactivity against endocrine cells - Google Patents

Ligands, including antibodies, showing reactivity against endocrine cells

Info

Publication number
IL133277A0
IL133277A0 IL13327798A IL13327798A IL133277A0 IL 133277 A0 IL133277 A0 IL 133277A0 IL 13327798 A IL13327798 A IL 13327798A IL 13327798 A IL13327798 A IL 13327798A IL 133277 A0 IL133277 A0 IL 133277A0
Authority
IL
Israel
Prior art keywords
antibodies
ligands
endocrine cells
including antibodies
reactivity against
Prior art date
Application number
IL13327798A
Other languages
English (en)
Original Assignee
Rogers Arpi Matossian
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9715281A external-priority patent/GB2327423B/en
Priority claimed from GBGB9810676.8A external-priority patent/GB9810676D0/en
Application filed by Rogers Arpi Matossian filed Critical Rogers Arpi Matossian
Publication of IL133277A0 publication Critical patent/IL133277A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
IL13327798A 1997-07-21 1998-07-20 Ligands, including antibodies, showing reactivity against endocrine cells IL133277A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9715281A GB2327423B (en) 1997-07-21 1997-07-21 Ligands, including antibodies, showing reactivity against endocrine cells for use in therapy and diagnosis
GBGB9810676.8A GB9810676D0 (en) 1998-05-18 1998-05-18 Ligands including antibodies showing reactivity against endocrine cells for use in therapy and diagnosis
PCT/GB1998/002151 WO1999005175A2 (en) 1997-07-21 1998-07-20 Diagnosis and treatment of diseases using anti-anti-t-cell receptor vbeta anti-bodies or peptides which are recognized by said antibodies, and endocrine secretion regulatory protein i (esrp1)

Publications (1)

Publication Number Publication Date
IL133277A0 true IL133277A0 (en) 2001-04-30

Family

ID=26311906

Family Applications (3)

Application Number Title Priority Date Filing Date
IL13327798A IL133277A0 (en) 1997-07-21 1998-07-20 Ligands, including antibodies, showing reactivity against endocrine cells
IL133277A IL133277A (en) 1997-07-21 1999-12-02 Ligands, including antibodies, show a response against endocrine cells
IL176076A IL176076A (en) 1997-07-21 2006-05-31 Polypeptides and their segments bound by an antibody or segment of an antibody that responds to an anti-TCR V beta antibody and their uses

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL133277A IL133277A (en) 1997-07-21 1999-12-02 Ligands, including antibodies, show a response against endocrine cells
IL176076A IL176076A (en) 1997-07-21 2006-05-31 Polypeptides and their segments bound by an antibody or segment of an antibody that responds to an anti-TCR V beta antibody and their uses

Country Status (21)

Country Link
US (2) US6689359B1 (de)
EP (2) EP0998556B1 (de)
JP (1) JP2002511765A (de)
KR (2) KR100567277B1 (de)
CN (1) CN1330754C (de)
AT (1) ATE297983T1 (de)
AU (1) AU758455B2 (de)
BR (1) BR9810118A (de)
CA (1) CA2296842C (de)
CU (1) CU23412A3 (de)
DE (1) DE69830588T2 (de)
DK (1) DK0998556T3 (de)
EA (1) EA003131B1 (de)
ES (1) ES2245034T3 (de)
IL (3) IL133277A0 (de)
NZ (1) NZ501424A (de)
PL (1) PL204503B1 (de)
PT (1) PT998556E (de)
SI (1) SI0998556T1 (de)
TR (1) TR200000181T2 (de)
WO (1) WO1999005175A2 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003510049A (ja) * 1999-09-23 2003-03-18 ライジェル・ファーマシューティカルズ・インコーポレイテッド Ｔｒａｆ４関連細胞周期タンパク質、組成物および使用法
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
GB2429013C (en) * 2005-08-11 2012-11-28 Arpi Matossian-Rogers Peptides for treatment and diagnosis of autoimmunedisease
AU2012241141B2 (en) * 2005-08-11 2015-08-20 Arpi Matossian-Rogers TCR-V-beta related peptides for treatment and diagnosis of autoimmune disease
BRPI0619249A2 (pt) 2005-11-30 2011-09-20 Abbott Lab anticorpos anti-globulÈmeros-aß, frações que se ligam a antìgeno destes, hibridomas correspondentes, ácidos nucléicos, vetores, células hospedeiras, métodos de produzir os ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos de usar os ditos anticorpos
PT1976877E (pt) 2005-11-30 2014-04-29 Abbvie Inc Anticorpos monoclonais contra proteína beta-amilóide e suas utilizações
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2124952A2 (de) 2007-02-27 2009-12-02 Abbott GmbH & Co. KG Verfahren zur behandlung von amyloidosen
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
EP2586795B1 (de) 2007-10-05 2018-05-16 Genentech, Inc. Verwendung eines Anti-Amyloid-Beta-Antikörpers bei Augenkrankheiten
EP2558494B1 (de) 2010-04-15 2018-05-23 AbbVie Inc. Amyloid-beta-bindende proteine
AU2011282536B2 (en) 2010-07-30 2015-12-24 Ac Immune S.A. Safe and functional humanized anti beta-amyloid antibody
CN105348387B (zh) 2010-08-14 2020-08-25 Abbvie 公司 β淀粉样蛋白结合蛋白
KR101640694B1 (ko) * 2011-09-29 2016-07-18 셀스냅, 엘엘씨 독소생산능 시험용 조성물 및 방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2072356A1 (en) * 1989-12-29 1991-06-30 James L. Urban Diagnosis and treatment of diseases
US5216132A (en) * 1990-01-12 1993-06-01 Protein Design Labs, Inc. Soluble t-cell antigen receptor chimeric antigens
JPH06507384A (ja) 1991-01-22 1994-08-25 ザ　イミューン　レスポンス　コーポレイション 特定のｔ細胞群による病理的応答により生じる疾患に対するワクチン投与および方法
US5480895A (en) * 1991-09-27 1996-01-02 New York Society For The Relief Of The Ruptured And Crippled, Maintaining The Hospital For Special Surgery Method of producing antibodies to a restricted population of T lymphocytes, antibodies produced therefrom and methods of use thereof
US5891623A (en) * 1992-11-09 1999-04-06 Consorzio Per Le Biotecnologie Diagnosis and treatment of AIDS onset
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
US5589328A (en) * 1994-08-04 1996-12-31 Mahant; Vijay K. Chemiluminescence assays based on indoxyl substrates, thioindoxyl substrates and other substrates

Also Published As

Publication number Publication date
PT998556E (pt) 2005-09-30
WO1999005175A3 (en) 1999-06-10
AU758455B2 (en) 2003-03-20
ATE297983T1 (de) 2005-07-15
CN1264426A (zh) 2000-08-23
TR200000181T2 (tr) 2000-05-22
PL338449A1 (en) 2000-11-06
CU23412A3 (es) 2009-09-08
EA003131B1 (ru) 2003-02-27
IL176076A0 (en) 2006-10-05
SI0998556T1 (en) 2005-10-31
EA200000146A1 (ru) 2000-10-30
CN1330754C (zh) 2007-08-08
EP1595951A1 (de) 2005-11-16
KR20010022063A (ko) 2001-03-15
NZ501424A (en) 2005-08-26
KR100567277B1 (ko) 2006-04-05
PL204503B1 (pl) 2010-01-29
CA2296842A1 (en) 1999-02-04
KR20050046825A (ko) 2005-05-18
ES2245034T3 (es) 2005-12-16
US20050100541A1 (en) 2005-05-12
AU8451798A (en) 1999-02-16
DK0998556T3 (da) 2005-10-17
DE69830588D1 (de) 2005-07-21
IL133277A (en) 2006-09-05
US6689359B1 (en) 2004-02-10
CA2296842C (en) 2012-03-20
EP0998556B1 (de) 2005-06-15
BR9810118A (pt) 2000-08-08
EP0998556A2 (de) 2000-05-10
WO1999005175A2 (en) 1999-02-04
JP2002511765A (ja) 2002-04-16
DE69830588T2 (de) 2006-05-04
IL176076A (en) 2010-06-16
KR100670070B1 (ko) 2007-01-19

Similar Documents

Publication Publication Date Title
IL176076A0 (en) Ligands,including antibodies showing, reactivity against endocrine cells
MXPA02011656A (es) Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos.
NZ513498A (en) Monoclonal antibodies, antigens and diagnosis and therapy of malignant diseases
AU4201197A (en) An immunological method for detecting antibodies directed against tissue transglutaminase (TTG), use of TTG in diagnosis and therapy control, and an oral pharmaceutical agent containing TTG
WO2001096388A8 (en) Compositions and methods for the therapy and diagnosis of colon cancer
DK1307564T3 (da) Forbindelser og fremgangsmåde til behandling og diagnose af chlamydiainfektion
WO2000004149A3 (en) Compositions and methods for therapy and diagnosis of prostate cancer
WO2000037643A3 (en) Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
ATE421531T1 (de) Apoptose-bezogene verbindungen und deren verwendung
AU7312801A (en) Compositions and methods for the diagnosis and treatment of herpes simplex virusinfection
WO2001049716A3 (en) Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
DK0687180T3 (da) Fremgangsmåde til påvisning og behandling af individer, som har unormale celler, som udtrykker HLC-A2/tyrosinasepeptid-anti
EP0834567A3 (de) Zusammensetzungen und Verfahren zur Diagnose und Behandlung von Babesia microti Infektion
WO2000078960A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer
WO2001096372A3 (en) Zinc transporters proteins and their use in medicinal preparations
NO962596L (no) Nytt tumorsupressorgen
WO2001096389A3 (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU4098201A (en) Method for diagnosing efficacy of xenotypic antibody therapy
WO1999051725A3 (en) Assay for the diagnosis of schizophrenia based on a new peptide
DE50015355D1 (de) Mit trp-proteinen verwandtes protein mtr1 und dieses codierende dna-sequenz
WO2002012332A3 (en) Compositions and methods for the therapy and diagnosis of colon cancer
WO2002034282A3 (en) Mammary secreted protein 36 (msp36) for cancer treatment and diagnosis
GB9715177D0 (en) Medicament
WO2002012476A3 (en) Compositions and methods for the therapy and diagnosis of pancreatic cancer
WO2001027276A3 (en) Dna sequences from breast tumor and uses thereof

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed